Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this presentation? Why not share!




very easy

very easy



Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds



Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • Kristin Sainani Ph.D. http://www.stanford.edu/~kcobb Stanford University Department of Health Research and Policy
  • Note: also the recent diabetes study in a Swedish population, where they reduced heart disease 50% among type II diabetics. Very tough intervention. Multiple drugs. Attempts to quit smoking. Diet and exercise. Not everyone participated fully; for example, smoking cessation was utter failure. If everyone had participated more fully in the regime, there might have even been a stronger effect.
  • See all lectures from this course

33111 33111 Presentation Transcript

  • Cox Regression II Kristin Sainani Ph.D. http:// www.stanford.edu/~kcobb Stanford University Department of Health Research and Policy
  • Topics
    • Stratification
    • Age as time scale
    • Residuals
    • Repeated events
    • Intention-to-treat analysis for RCTs
  • 1. Stratification
    • Violations of PH assumption can be resolved by:
        • Adding time*covariate interaction
        • Adding other time-dependent version of the covariate
        • Stratification
  • Stratification
    • Different stratum are allowed to have different baseline hazard functions.
    • Hazard functions do not need to be parallel between different stratum.
    • Essentially results in a “weighted” hazard ratio being estimated: weighted over the different strata.
    • Useful for “nuisance” confounders (where you do not care to estimate the effect).
    • Does not allow you to evaluate interaction or confounding of stratification variable (will miss possible interactions).
    • Males: 1, 3, 4, 10+, 12, 18 (subjects 1-6)
    • Females: 1, 4, 5, 9+ (subjects 7-10)
    Example: stratify on gender ♀ ♂ ♀ ♀ ♂ ♂
  • The PL ♀ ♂
    • Age is a common confounder in Cox Regression, since age is strongly related to death and disease.
    • You may control for age by adding baseline age as a covariate to the Cox model.
    • A better strategy for large-scale longitudinal surveys, such as NHANES, is to use age as your time-scale (rather than time-in-study).
    • You may additionally stratify on birth cohort to control for cohort effects.
    2. Using age as the time-scale in Cox Regression
  • Age as time-scale
    • The risk set becomes everyone who was at risk at a certain age rather than at a certain event time.
    • The risk set contains everyone who was still event-free at the age of the person who had the event.
    • Requires enough people at risk at all ages (such as in a large-scale, longitudinal survey).
  • The likelihood with age as time Event times: 3, 5, 7+, 12, 13+ (years-in-study) Baseline ages: 28, 25, 40, 29, 30 (years) Age at event or censoring: 31, 30, 47+, 41, 43+
  • 3. Residuals
    • Residuals are used to investigate the lack of fit of a model to a given subject.
    • For Cox regression, there’s no easy analog to the usual “observed minus predicted” residual of linear regression
  • Martingale residual
    • c i (1 if event, 0 if censored) minus the estimated cumulative hazard to t i (as a function of fitted model) for individual i:
    • c i -H(t i ,X i ,  ß i )
        • E.g., for a subject who was censored at 2 months, and whose predicted cumulative hazard to 2 months was 20%
          • Martingale=0-.20 = -.20
        • E.g., for a subject who had an event at 13 months, and whose predicted cumulative hazard to 13 months was 50%:
          • Martingale=1-.50 = +.50
    • Gives excess failures.
    • Martingale residuals are not symmetrically distributed, even when the fitted model is correctly, so transform to deviance residuals ...
  • Deviance Residuals
    • The deviance residual is a normalized transform of the martingale residual. These residuals are much more symmetrically distributed about zero.
    • Observations with large deviance residuals are poorly predicted by the model.
  • Deviance Residuals
    • Behave like residuals from ordinary linear regression
    • Should be symmetrically distributed around 0 and have standard deviation of 1.0.
    • Negative for observations with longer than expected observed survival times.
    • Plot deviance residuals against covariates to look for unusual patterns.
  • Deviance Residuals
    • In SAS, option on the output statement:
    • Output out=outdata resdev = Varname
    • ** Cannot get diagnostics in SAS if time-dependent covariate in the model
  • Example: uis data Pattern looks fairly symmetric around 0. Out of 628 observations, a few in the range of 3-SD is not unexpected
  • Example: uis data What do you think this cluster represents?
  • Example: censored only
  • Example: had event only
  • Schoenfeld residuals
    • Schoenfeld (1982) proposed the first set of residuals for use with Cox regression packages
      • Schoenfeld D. Residuals for the proportional hazards regresssion model. Biometrika , 1982, 69(1):239-241.
    • Instead of a single residual for each individual, there is a separate residual for each individual for each covariate
    • Note: Schoenfeld residuals are not defined for censored individuals.
  • Schoenfeld residuals
    • The Schoenfeld residual is defined as the covariate value for the individual that failed minus its expected value. (Yields residuals for each individual who failed, for each covariate).
    • Expected value of the covariate at time t i = a weighted-average of the covariate, weighted by the likelihood of failure for each individual in the risk set at t i .
    The person who died was 56; based on the fitted model, how likely is it that the person who died was 56 rather than older?
  • Example
    • 5 people left in our risk set at event time=7 months:
        • Female 55-year old smoker
        • Male 45-year old non-smoker
        • Female 67-year old smoker
        • Male 58-year old smoker
        • Male 70-year old non-smoker
        • The 55-year old female smoker is the one who has the event…
  • Example
    • Based on our model, we can calculate a predicted probability of death by time 7 for each person (call it “p-hat”):
        • Female 55-year old smoker: p-hat=.10
        • Male 45-year old non-smoker : p-hat=.05
        • Female 67-year old smoker : p-hat=.30
        • Male 58-year old smoker : p-hat=.20
        • Male 70-year old non-smoker : p-hat=.30
        • Thus, the expected value for the AGE of the person who failed is:
        • 55(.10) + 45 (.05) + 67(.30) + 58 (.20) + 70 (.30)= 60
        • And, the Schoenfeld residual is: 55-60 = -5
  • Example
    • Based on our model, we can calculate a predicted probability of death by time 7 for each person (call it “p-hat”):
        • Female 55-year old smoker: p-hat=.10
        • Male 45-year old non-smoker : p-hat=.05
        • Female 67-year old smoker : p-hat=.30
        • Male 58-year old smoker : p-hat=.20
        • Male 70-year old non-smoker : p-hat=.30
        • The expected value for the GENDER of the person who failed is:
        • 0(.10) + 1(.05) + 0(.30) + 1 (.20) + 1 (.30)= .55
        • And, the Schoenfeld residual is: 0-.55 = -.55
  • Schoenfeld residuals
    • Since the Schoenfeld residuals are, in principle, independent of time, a plot that shows a non-random pattern against time is evidence of violation of the PH assumption .
      • Plot Schoenfeld residuals against time to evaluate PH assumption
      • Regress Schoenfeld residuals against time to test for independence between residuals and time.
  • Example: no pattern with time
  • Example: violation of PH
  • Schoenfeld residuals
    • In SAS:
    • option on the output statement:
    • Output out=outdata ressch= Covariate1 Covariate2 Covariate3
  • Summary of the many ways to evaluate PH assumption…
    • 1. Examine log(-log(S(t)) plots
        • PH assumption is supported by parallel lines and refuted by lines that cross or nearly cross
        • Must use categorical predictors or categories of a continuous predictor
    • 2. Include interaction with time in the model
        • PH assumption is supported by non-significant interaction coefficient and refuted by significant interaction coefficient
        • Retaining the interaction term in the model corrects for the violation of PH
        • Don’t complicate your model in this way unless it’s absolutely necessary!
    • 3. Plot Schoenfeld residuals
        • PH assumption is supported by a random pattern with time and refuted by a non-random pattern
    • 4. Regress Schoenfeld residuals against time to test for independence between residuals and time.
        • PH assumption is supported by a non-significant relationship between residuals and time, and refuted by a significant relationship
    • Death (presumably) can only happen once, but many outcomes could happen twice…
      • Fractures
      • Heart attacks
      • Pregnancy
      • Etc…
    4. Repeated events
    • Strategy 1: run a second Cox regression (among those who had a first event) starting with first event time as the origin
    • Repeat for third, fourth, fifth, events, etc.
      • Problems: increasingly smaller and smaller sample sizes.
    Repeated events: 1
    • Treat each interval as a distinct observation, such that someone who had 3 events, for example, gives 3 observations to the dataset
      • Major problem: dependence between the same individual
    Repeated events: Strategy 2
    • Stratify by individual (“fixed effects partial likelihood”)
    • In PROC PHREG: strata id;
      • Problems:
      • does not work well with RCT data
      • requires that most individuals have at least 2 events
      • Can only estimate coefficients for those covariates that vary across successive spells for each individual; this excludes constant personal characteristics such as age, education, gender, ethnicity, genotype
    Strategy 3
  • 5. Considerations when analyzing data from an RCT…
  • Intention-to-Treat Analysis
    • Intention-to-treat analysis: compare outcomes according to the groups to which subjects were initially assigned, regardless of which intervention they actually received.
    • Evaluates treatment effectiveness rather than treatment efficacy
  • Why intention to treat?
    • Non-intention-to-treat analyses lose the benefits of randomization, as the groups may no longer be balanced with regards to factors that influence the outcome.
    • Intention-to-treat analysis simulates “real life,” where patients often don’t adhere perfectly to treatment or may discontinue treatment altogether.
  • Drop-ins and Drop-outs: example, WHI Women’s Health Initiative Writing Group. JAMA . 2002;288:321-333. Both women on placebo and women on active treatment discontinued study medications. Women on placebo “dropped in” to treatment because their regular doctors put them on hormones (dogma= “hormones are good”). Women on treatment “dropped in” to treatment because their doctors took them off study drugs and put them on hormones to insure they were on hormones and not placebo.
  • Effect of Intention to treat on the statistical analysis
    • Intention-to-treat analyses tend to underestimate treatment effects; increased variability “waters down” results.
  • Example
    • Take the following hypothetical RCT:
    • Treated subjects have a 25% chance of dying during the 2-year study vs. placebo subjects have a 50% chance of dying.
    • TRUE RR= 25%/50% = .50 (treated have 50% less chance of dying)
    • You do a 2-yr RCT of 100 treated and 100 placebo subjects.
    • If nobody switched, you would see about 25 deaths in the treated group and about 50 deaths in the placebo group (give or take a few due to random chance).
    •  Observed RR  .50
  • Example, continued
    • BUT, if early in the study, 25 treated subjects switch to placebo and 25 placebo subjects switch to control.
    • You would see about
      • 25*.25 + 75*.50 = 43-44 deaths in the placebo group
    • And about
      • 25*.50 + 75*.25 = 31 deaths in the treated group
      • Observed RR = 31/44  .70
      • Diluted effect!
  • References
    • Paul Allison. Survival Analysis Using SAS . SAS Institute Inc., Cary, NC: 2003.